Cargando…
Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal‐epithelial transition pathway is frequently observed. Here, we report that HC...
Autores principales: | Chen, Weibo, Yang, Junsheng, Zhang, Yue, Cai, Huihua, Chen, Xuemin, Sun, Donglin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356182/ https://www.ncbi.nlm.nih.gov/pubmed/30761258 http://dx.doi.org/10.1002/2211-5463.12578 |
Ejemplares similares
-
Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022) -
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016) -
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021) -
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017) -
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2016)